September 28, 2016 Foamix Pharmaceuticals Ltd. Announces Pricing of its $57 Million Follow-on Offering of Ordinary Shares View Article
September 12, 2016 Foamix Announces Positive Topline Results from Phase 2 Trial Evaluating FMX-103 Topical Minocycline Foam for Moderate-to-Severe Papulopustular Rosacea View Article
May 31, 2016 Foamix Pharmaceuticals Announces Publication of Abstract on FDX-104 in the Treatment of EGFRI Induced Rash for the 2016 ASCO Meeting View Article
May 16, 2016 Foamix Names Dr. Stanley Hirsch as Chairman, and Dr. Dalia Megiddo as a Member of the Board of Foamix Pharmaceuticals View Article
May 10, 2016 Foamix Reports First Quarter 2016 Financial Results and Provides Business Update View Article
May 9, 2016 Foamix Announces Dosing of First Patient in Phase 3 Acne Studies for Minocycline Foam FMX101 View Article
May 3, 2016 Foamix Announces Completion of Enrollment in Phase 2 Clinical Trial of Minocycline Foam (FMX103) for Treatment of Papulopustular Rosacea View Article
March 3, 2016 Foamix Reports Fiscal Year 2015 Financial Results and Provides Business Update View Article
October 20, 2015 Foamix Announces Enrollment of First Patient in Phase 2 Clinical Trial of FMX103 in Papulopustular Rosacea View Article
July 31, 2015 Bayer HealthCare and Foamix Pharmaceuticals, Ltd. Release: Finacea (Azelaic Acid) Foam 15%, Approved By U.S. FDA For Topical Treatment Of The Inflammatory Papules And Pustules Of Mild To Moderate Rosacea View Article
